AstraZeneca’s (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Wednesday morning, MarketBeat Ratings reports.

Other equities analysts have also issued reports about the company. Berenberg Bank reissued a “buy” rating and issued a GBX 140 ($1.77) price objective on shares of AstraZeneca in a report on Monday, January 27th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of GBX 7,542.80 ($95.30).

AstraZeneca Price Performance

Shares of LON AZN opened at £117.08 ($147.92) on Wednesday. The business’s fifty day moving average price is £109.99 and its two-hundred day moving average price is £114.67. The firm has a market capitalization of £225.27 billion, a PE ratio of 32.09, a P/E/G ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 1-year low of GBX 9,670 ($122.17) and a 1-year high of £133.88 ($169.15).

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.